ADC Therapeutics (ADCT) Total Current Liabilities (2019 - 2026)

ADC Therapeutics has disclosed Total Current Liabilities across 8 years of filings, most recently posting $67.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $67.6 million, up 17.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.6 million (up 17.02% YoY), and the FY2025 annual result was $70.2 million, down 12.81% from the prior year.
• Total Current Liabilities came in at $67.6 million for Q1 2026 at ADC Therapeutics, down from $70.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $81.9 million in Q4 2022 to a low of $57.6 million in Q2 2024.
• The 5-year median for Total Current Liabilities is $67.6 million (2026), against an average of $67.3 million.
• Across the five-year window, Total Current Liabilities dropped 17.41% in 2023 and climbed 18.91% in 2024, its largest moves.
• ADC Therapeutics' Total Current Liabilities stood at $81.9 million in 2022, then declined by 17.41% to $67.7 million in 2023, then gained by 18.91% to $80.5 million in 2024, then retreated by 12.81% to $70.2 million in 2025, then retreated by 3.61% to $67.6 million in 2026.
• The last three Total Current Liabilities figures came in at $67.6 million (Q1 2026), $70.2 million (Q4 2025), and $62.0 million (Q3 2025), per Business Quant data.